Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522249 · ClinicalTrials.gov registry record · Phase 1
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00522249 is a Phase 1 study that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 10 participants.
The verdict
NCT00522249, a Phase 1 study, was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell Carcinoma. The first phase of this study will determine the best dose of Peg-Intron, Sunitinib and Tarceva when given in combination. The safety of giving these drugs in combination and response to treatment will also be examined.
Interventions
- DRUG sunitinib
- DRUG erlotinib
- DRUG Pegylated Alfa Interferon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00522249
The ClinicalTrials.gov registry entry for NCT00522249 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which sunitinib is the first listed.
NCT00522249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00522249 about?
NCT00522249 is a clinical study titled "Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC". The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell Carcinoma. The first phase of this study will determine the best dose of Peg...
What is the current status of trial NCT00522249?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2007-05. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00522249?
The interventions under investigation include: sunitinib (DRUG), erlotinib (DRUG), Pegylated Alfa Interferon (DRUG).
Who is sponsoring clinical trial NCT00522249?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.